Special Section on Cancer Gene Therapy
Cancer therapy with genetically-modified T cells for the treatment of melanoma
Article first published online: 27 JUN 2012
Published 2012. This article is a US Government work and is in the public domain in the USA.
The Journal of Gene Medicine
Volume 14, Issue 6, pages 400–404, June 2012
How to Cite
Lagisetty, K. H. and Morgan, R. A. (2012), Cancer therapy with genetically-modified T cells for the treatment of melanoma. J. Gene Med., 14: 400–404. doi: 10.1002/jgm.2636
- Issue published online: 27 JUN 2012
- Article first published online: 27 JUN 2012
- Accepted manuscript online: 18 MAY 2012 04:29PM EST
- Manuscript Accepted: 4 MAY 2012
- Manuscript Received: 3 FEB 2012
The aim of this review is to acquaint the reader with the concept of T cell receptor (TCR) gene therapy for metastatic melanoma. We first review antigen choice, followed by gene delivery technology and, finally, we discuss selected clinical applications. To be successful, TCR gene therapy must combine multiple elements and research disciplines. First, there is a need for an understanding of tumor immunology because this is essential in proper antigen choice. Second, gene therapy is a technology-driven field and cutting edge knowledge of protein engineering and gene delivery methods are indispensable. Finally, a dedicated team of physician/scientists and healthcare providers is fundamental to clinical success. TCR gene therapy is now a realistic treatment option for metastatic melanoma. Both tumor regression and on-target/off-tumor toxicities have been observed, which emphasizes the experimental nature of this approach. As with any new medical procedure, future large-scale randomized trials will be necessary to validate this approach, and these are within reason in the next few years. This article is a US Government work and is in the public domain in the USA.